Maximizing protection from use of oral cholera vaccines in developing country settings

References

• Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, Croucher NJ, Choi SY, Harris SR, Lebens M, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature 2011; 477:462 - 5; http://dx.doi.org/10.1038/nature10392; PMID: 21866102
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cholera, 2012. Wkly Epidemiol Rec 2013; 88:321 - 34; PMID: 23980290
   PubMedGoogle Scholar
• World Health Organization. Countries reporting cholera cases 2011. Global Health Observatory Map Gallery. September 28, 2012 [cited September 30, 2013].
   Google Scholar
• Enserink M. Public health. No vaccines in the time of cholera. Science 2010; 329:1462 - 3; http://dx.doi.org/10.1126/science.329.5998.1462; PMID: 20847246
   PubMed Web of Science ®Google Scholar
• Nossiter A. Cholera epidemic envelops coastal slums in West Africa, in New York TImes: Dakar, Senegal.
   Google Scholar
• Ministere de la Sante Publique et de la Population, Republique d'Haiti (MSPP). 2013 [cited; Available from: http://www.mspp.gouv.ht/site/index.php?option=com_content&view=article&id=120&Itemid=1.
   Google Scholar
• Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J. The global burden of cholera. Bull World Health Organ 2012; 90:209 - 218A; http://dx.doi.org/10.2471/BLT.11.093427; PMID: 22461716
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366:44 - 9; http://dx.doi.org/10.1016/S0140-6736(05)66550-6; PMID: 15993232
   PubMed Web of Science ®Google Scholar
• Longini, I.M., Jr., et al., Controlling endemic cholera with oral vaccines. PLoS Medicine / Public Library of Science, 2007. 4(11): p. e336.
   Google Scholar
• Pastor M, Pedraz JL, Esquisabel A. The state-of-the-art of approved and under-development cholera vaccines. Vaccine 2013; 31:4069 - 78; http://dx.doi.org/10.1016/j.vaccine.2013.06.096; PMID: 23845813
   PubMed Web of Science ®Google Scholar
• Sánchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005; 17:388 - 98; http://dx.doi.org/10.1016/j.coi.2005.06.007; PMID: 15963708
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:Suppl S45 - 53; http://dx.doi.org/10.1038/nm1213; PMID: 15812489
   PubMed Web of Science ®Google Scholar
• Cash RA, Music SI, Libonati JP, Craig JP, Pierce NF, Hornick RB. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 1974; 130:325 - 33; http://dx.doi.org/10.1093/infdis/130.4.325; PMID: 4443613
   PubMed Web of Science ®Google Scholar
• Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis 1994; 169:709 - 10; http://dx.doi.org/10.1093/infdis/169.3.709; PMID: 8158063
   PubMed Web of Science ®Google Scholar
• Mosley WH, Ahmad S, Benenson AS, Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ 1968; 38:777 - 85; PMID: 5303331
   PubMed Web of Science ®Google Scholar
• Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, LaRocque RC, Wrammert J, Ryan ET, et al. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 2009; 77:3850 - 6; http://dx.doi.org/10.1128/IAI.00369-09; PMID: 19528207
   PubMed Web of Science ®Google Scholar
• Clemens JD, Stanton BF, Chakraborty J, Sack DA, Khan MR, Huda S, Ahmed F, Harris JR, Yunus M, Khan MU, et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 1987; 155:79 - 85; http://dx.doi.org/10.1093/infdis/155.1.79; PMID: 3540139
   PubMed Web of Science ®Google Scholar
• Patel SM, Rahman MA, Mohasin M, Riyadh MA, Leung DT, Alam MM, Chowdhury F, Khan AI, Weil AA, Aktar A, et al. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin Vaccine Immunol 2012; 19:842 - 8; http://dx.doi.org/10.1128/CVI.00037-12; PMID: 22518009
   PubMed Web of Science ®Google Scholar
• O’Connor D, Pollard AJ. Characterizing vaccine responses using host genomic and transcriptomic analysis. Clin Infect Dis 2013; 57:860 - 9; http://dx.doi.org/10.1093/cid/cit373; PMID: 23728145
   PubMed Web of Science ®Google Scholar
• Faruque AS, Mahalanabis D, Hoque SS, Albert MJ. The relationship between ABO blood groups and susceptibility to diarrhea due to Vibrio cholerae 0139. Clin Infect Dis 1994; 18:827 - 8; http://dx.doi.org/10.1093/clinids/18.5.827; PMID: 8075282
   PubMed Web of Science ®Google Scholar
• Lagos R, Avendaño A, Prado V, Horwitz I, Wasserman S, Losonsky G, Cryz S Jr., Kaper JB, Levine MM. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun 1995; 63:707 - 9; PMID: 7822046
   PubMed Web of Science ®Google Scholar
• Chowdhury F, Khan AI, Harris JB, LaRocque RC, Chowdhury MI, Ryan ET, Faruque AS, Calderwood SB, Qadri F. A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis J 2008; 27:986 - 92; http://dx.doi.org/10.1097/INF.0b013e3181783adf; PMID: 18833030
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rappuoli R. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev 2006; 58:29 - 51; http://dx.doi.org/10.1016/j.addr.2005.12.002; PMID: 16480788
   PubMed Web of Science ®Google Scholar
• Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, et al, Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379:2151 - 61; http://dx.doi.org/10.1016/S0140-6736(12)60560-1; PMID: 22579125
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011; 239:125 - 48; http://dx.doi.org/10.1111/j.1600-065X.2010.00970.x; PMID: 21198669
   PubMed Web of Science ®Google Scholar
• Sack DA, Svennerholm AM. Determinants of Responses to Oral Vaccines in Developing Countries.. Ann Nestle 2008; 66:71 - 9; http://dx.doi.org/10.1159/000159366
   Google Scholar
• Qadri F, Bhuiyan TR, Sack DA, Svennerholm AM. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 2013; 31:452 - 60; http://dx.doi.org/10.1016/j.vaccine.2012.11.012; PMID: 23153448
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, Park JK, Yunus M, Clemens J. Natural cholera infection-derived immunity in an endemic setting. J Infect Dis 2011; 204:912 - 8; http://dx.doi.org/10.1093/infdis/jir416; PMID: 21849288
   PubMed Web of Science ®Google Scholar
• Leung DT, Rahman MA, Mohasin M, Riyadh MA, Patel SM, Alam MM, Chowdhury F, Khan AI, Kalivoda EJ, Aktar A, et al. Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol 2011; 18:1317 - 25; http://dx.doi.org/10.1128/CVI.05124-11; PMID: 21697337
   PubMed Web of Science ®Google Scholar
• Uddin T, Aktar A, Xu P, Johnson RA, Rahman MA, Leung DT, Afrin S, Akter A, Alam MM, Rahman A, et al. Immune Responses to O-Specific Polysaccharide and Lipopolysaccharide of Vibrio cholerae O1 Ogawa in Adult Bangladeshi Recipients of an Oral Killed Cholera Vaccine and Comparison to Responses in Patients with Cholera. Am J Trop Med Hyg 2014; 90:873 - 81; http://dx.doi.org/10.4269/ajtmh.13-0498; PMID: 24686738
   PubMed Web of Science ®Google Scholar
• Leung DT, Rahman MA, Mohasin M, Patel SM, Aktar A, Khanam F, Uddin T, Riyadh MA, Saha A, Alam MM, et al. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol 2012; 19:690 - 8; http://dx.doi.org/10.1128/CVI.05615-11; PMID: 22441386
   PubMed Web of Science ®Google Scholar
• Arifuzzaman M, Rashu R, Leung DT, Hosen MI, Bhuiyan TR, Bhuiyan MS, Rahman MA, Khanam F, Saha A, Charles RC, et al. Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin Vaccine Immunol 2012; 19:1304 - 11; http://dx.doi.org/10.1128/CVI.00196-12; PMID: 22739692
   PubMed Web of Science ®Google Scholar
• Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr 2010; 156:Suppl S3 - 7; http://dx.doi.org/10.1016/j.jpeds.2009.11.021; PMID: 20105662
   PubMed Web of Science ®Google Scholar
• Glass RI, Svennerholm AM, Stoll BJ, Khan MR, Hossain KM, Huq MI, Holmgren J. Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med 1983; 308:1389 - 92; http://dx.doi.org/10.1056/NEJM198306093082304; PMID: 6843632
   PubMed Web of Science ®Google Scholar
• Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003; 21:3406 - 12; http://dx.doi.org/10.1016/S0264-410X(03)00342-6; PMID: 12850349
   PubMed Web of Science ®Google Scholar
• Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 2009; 27:1433 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.12.036; PMID: 19146904
   PubMed Web of Science ®Google Scholar
• Glass RI, Stoll BJ. The protective effect of human milk against diarrhea. A review of studies from Bangladesh. Acta Paediatr Scand Suppl 1989; 351:131 - 6; http://dx.doi.org/10.1111/j.1651-2227.1989.tb11225.x; PMID: 2692384
   PubMedGoogle Scholar
• Clemens JD, Sack DA, Harris JR, Khan MR, Chakraborty J, Chowdhury S, Rao MR, van Loon FP, Stanton BF, Yunus M, et al. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol 1990; 131:400 - 11; PMID: 2301350
   PubMed Web of Science ®Google Scholar
• Khan AM, Hossain MS, Khan AI, Chisti MJ, Chowdhury F, Faruque AS, Salam MA. Bacterial enteropathogens of neonates admitted to an urban diarrhoeal hospital in Bangladesh. J Trop Pediatr 2009; 55:122 - 4; http://dx.doi.org/10.1093/tropej/fmn090; PMID: 18840632
   PubMed Web of Science ®Google Scholar
• Siddique AK, Ahmed S, Iqbal A, Sobhan A, Poddar G, Azim T, Sack DA, Rahman M, Sack RB. Epidemiology of rotavirus and cholera in children aged less than five years in rural Bangladesh. J Health Popul Nutr 2011; 29:1 - 8; http://dx.doi.org/10.3329/jhpn.v29i1.7560; PMID: 21528784
   PubMed Web of Science ®Google Scholar
• Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, Mathers C, Rivera J, Maternal and Child Undernutrition Study Group. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008; 371:243 - 60; http://dx.doi.org/10.1016/S0140-6736(07)61690-0; PMID: 18207566
   PubMed Web of Science ®Google Scholar
• Palmer DL, Koster FT, Alam AK, Islam MR. Nutritional status: a determinant of severity of diarrhea in patients with cholera. J Infect Dis 1976; 134:8 - 14; http://dx.doi.org/10.1093/infdis/134.1.8; PMID: 820813
   PubMed Web of Science ®Google Scholar
• Cassani B, Villablanca EJ, De Calisto J, Wang S, Mora JR. Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. Mol Aspects Med 2012; 33:63 - 76; http://dx.doi.org/10.1016/j.mam.2011.11.001; PMID: 22120429
   PubMed Web of Science ®Google Scholar
• Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, Giovannucci E. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134:1129 - 40; http://dx.doi.org/10.1017/S0950268806007175; PMID: 16959053
   PubMed Web of Science ®Google Scholar
• Larson CP, Roy SK, Khan AI, Rahman AS, Qadri F. Zinc treatment to under-five children: applications to improve child survival and reduce burden of disease. J Health Popul Nutr 2008; 26:356 - 65; PMID: 18831230
   PubMed Web of Science ®Google Scholar
• Larson CP, Nasrin D, Saha A, Chowdhury MI, Qadri F. The added benefit of zinc supplementation after zinc treatment of acute childhood diarrhoea: a randomized, double-blind field trial. Trop Med Int Health 2010; 15:754 - 61; http://dx.doi.org/10.1111/j.1365-3156.2010.02525.x; PMID: 20374562
   PubMed Web of Science ®Google Scholar
• Brooks WA, Yunus M, Santosham M, Wahed MA, Nahar K, Yeasmin S, Black RE. Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial. Lancet 2004; 363:1683 - 8; http://dx.doi.org/10.1016/S0140-6736(04)16252-1; PMID: 15158629
   PubMed Web of Science ®Google Scholar
• Fischer Walker C, Black RE. Zinc and the risk for infectious disease. Annu Rev Nutr 2004; 24:255 - 75; http://dx.doi.org/10.1146/annurev.nutr.23.011702.073054; PMID: 15189121
   PubMed Web of Science ®Google Scholar
• Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr 2007; 98:Suppl 1 S29 - 35; http://dx.doi.org/10.1017/S0007114507832971; PMID: 17922955
   PubMed Web of Science ®Google Scholar
• Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010; 8:129; http://dx.doi.org/10.1186/1741-7007-8-129; PMID: 20920375
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, Aguilar M, Guevara A, Guderian RH, Levine MM, et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis 2000; 182:1199 - 206; http://dx.doi.org/10.1086/315837; PMID: 10979918
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335:270 - 3; http://dx.doi.org/10.1016/0140-6736(90)90080-O; PMID: 1967730
   PubMed Web of Science ®Google Scholar
• Anh DD, Canh G, Lopez AL, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007; 25:1149 - 55; http://dx.doi.org/10.1016/j.vaccine.2006.09.049; PMID: 17055622
   PubMed Web of Science ®Google Scholar
• Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. [Electronic Resource] PLoS One 2008; 3:e2323; http://dx.doi.org/10.1371/journal.pone.0002323; PMID: 18523643
   PubMed Web of Science ®Google Scholar
• Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 2011; 29:8285 - 92; http://dx.doi.org/10.1016/j.vaccine.2011.08.108; PMID: 21907255
   PubMed Web of Science ®Google Scholar
• Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Manna B, Kim DR, Han SH, Attridge S, Carbis R, Rao R, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009; 27:6887 - 93; http://dx.doi.org/10.1016/j.vaccine.2009.09.008; PMID: 19761838
   PubMed Web of Science ®Google Scholar
• Jertborn M, Svennerholm AM, Holmgren J. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine 1996; 14:1459 - 65; http://dx.doi.org/10.1016/S0264-410X(96)00071-0; PMID: 8994322
   PubMed Web of Science ®Google Scholar
• Alam MM, Riyadh MA, Fatema K, Rahman MA, Akhtar N, Ahmed T, Chowdhury MI, Chowdhury F, Calderwood SB, Harris JB, et al. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol 2011; 18:844 - 50; http://dx.doi.org/10.1128/CVI.00562-10; PMID: 21346055
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013; 13:1050 - 6; http://dx.doi.org/10.1016/S1473-3099(13)70273-1; PMID: 24140390
   PubMed Web of Science ®Google Scholar
• Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, et al. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine 2013; 31:6058 - 64; http://dx.doi.org/10.1016/j.vaccine.2013.10.021; PMID: 24161413
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:117 - 28; PMID: 20349546
   PubMedGoogle Scholar
• Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M, Clemens JD. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. [electronic resource] PLoS Negl Trop Dis 2008; 2:e173; http://dx.doi.org/10.1371/journal.pntd.0000173; PMID: 18299707
   PubMed Web of Science ®Google Scholar
• Desai SN, et al. Study of Alternative Vaccination Schedule of Oral Cholera Vaccine. NCT01233362. in Vaccines and Enteric Diseases. 2013. Bangkok.
   Google Scholar
• Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev Vaccines 2006; 5:483 - 94; http://dx.doi.org/10.1586/14760584.5.4.483; PMID: 16989629
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Kaper JB, Levine MM. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166:837 - 41; http://dx.doi.org/10.1093/infdis/166.4.837; PMID: 1527420
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399 - 410; http://dx.doi.org/10.1016/S0264-410X(00)00006-2; PMID: 10738097
   PubMed Web of Science ®Google Scholar
• Calain P, Chaine JP, Johnson E, Hawley ML, O’Leary MJ, Oshitani H, Chaignat CL. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine 2004; 22:2444 - 51; http://dx.doi.org/10.1016/j.vaccine.2003.11.070; PMID: 15193408
   PubMed Web of Science ®Google Scholar
• Suharyono A, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky G, Totosudirjo H, Rifai AR, Clemens J, Lim YL, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992; 340:689 - 94; http://dx.doi.org/10.1016/0140-6736(92)92231-4; PMID: 1355798
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, Lanata CF, Wasserman SS, Salazar E, Kaper JB, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994 - 7; PMID: 8359923
   PubMed Web of Science ®Google Scholar
• Simanjuntak CH, O’Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarso A, Rifai AR, et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis 1993; 168:1169 - 76; http://dx.doi.org/10.1093/infdis/168.5.1169; PMID: 8228350
   PubMed Web of Science ®Google Scholar
• Perry RT, Plowe CV, Koumaré B, Bougoudogo F, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ 1998; 76:63 - 71; PMID: 9615498
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, et al, PXV Study Group. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007; 25:231 - 8; http://dx.doi.org/10.1016/j.vaccine.2006.08.031; PMID: 16996172
   PubMed Web of Science ®Google Scholar
• Qadri F. (personal communication with PI) Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants. NCT00624975. 2013: Dhaka.
   Google Scholar
• Ratanasuwan W, Lee Y. A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Single Dose Regimen of Live Attenuated Oral Cholera Vaccine (Choleragarde®) in HIV-Seropositive Adults in Thailand. NCT00741637. in Presented at Vaccines and Enteric Diseases. 2013. Bangkok.
   Google Scholar
• Valera R, García HM, Jidy MD, Mirabal M, Armesto MI, Fando R, García L, Fernández R, Año G, Cedré B, et al. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults. Vaccine 2009; 27:6564 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.08.042; PMID: 19720365
   PubMed Web of Science ®Google Scholar
• Garcia HM, et al. (2011) A single dose of live-attenuated 638 Vibrio cholerae oral vaccine is safe and immunogenic in adult volunteers in Mozambique. VacciMonitor Volume, 1-8.
   Google Scholar
• Mahalanabis D, Ramamurthy T, Nair GB, Ghosh A, Shaikh S, Sen B, Thungapathra M, Ghosh RK, Pazhani GP, Nandy RK, et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 2009; 27:4850 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.05.065; PMID: 19523608
   PubMed Web of Science ®Google Scholar
• Jeuland M, Cook J, Poulos C, Clemens J, Whittington D, DOMI Cholera Economics Study Group. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health 2009; 12:899 - 908; http://dx.doi.org/10.1111/j.1524-4733.2009.00562.x; PMID: 19824189
   PubMed Web of Science ®Google Scholar
• Sarker AR, Islam Z, Khan IA, Saha A, Chowdhury F, Khan AI, Qadri F, Khan JA. Cost of illness for cholera in a high risk urban area in Bangladesh: an analysis from household perspective. BMC Infect Dis 2013; 13:518; http://dx.doi.org/10.1186/1471-2334-13-518; PMID: 24188717
   PubMed Web of Science ®Google Scholar
• International Vaccine Institute. An investment case for the accelerated introduction of oral cholera vaccines. Seoul, Korea.2012. [cited January 27, 2014]; Available from: http://www.ivi.int/web/www/04_03.
   Google Scholar
• Mogasale V, et al. Oral cholera vaccines to control endemic disease: an economic and epidemiological modelling analysis. Lancet 2013; 382:6; http://dx.doi.org/10.1016/S0140-6736(13)62167-4
   Web of Science ®Google Scholar
• World Health Organization. Cholera, 2011. Wkly Epidemiol Rec 2012; 87:289 - 304; PMID: 22905370
   PubMedGoogle Scholar
• Chao DL, Halloran ME, Longini IM Jr.. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci U S A 2011; 108:7081 - 5; http://dx.doi.org/10.1073/pnas.1102149108; PMID: 21482756
   PubMed Web of Science ®Google Scholar
• Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile--a new humanitarian and diplomatic resource. N Engl J Med 2010; 363:2279 - 82; http://dx.doi.org/10.1056/NEJMp1012300; PMID: 21105832
   PubMed Web of Science ®Google Scholar
• International Vaccine Institute. Cholera: Orissa mass vaccination Campaign. 2011 [cited February 1, 2013]; Available from: http://www.ivi.int/web/www/02_05_02.
   Google Scholar
• Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, Jerome JG, Hilaire IJ, Almazor CP, Ternier R, et al. Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg 2013; 89:617 - 24; http://dx.doi.org/10.4269/ajtmh.13-0183; PMID: 24106187
   PubMed Web of Science ®Google Scholar
• Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Dialo AA, Itama C, Serafini M, Legros D, et al. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl Trop Dis 2013; 7:e2465; http://dx.doi.org/10.1371/journal.pntd.0002465; PMID: 24147164
   PubMedGoogle Scholar
• Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, Ley B, Thriemer K, Enwere G, Hutubessy R, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 2012; 12:837 - 44; http://dx.doi.org/10.1016/S1473-3099(12)70196-2; PMID: 22954655
   PubMed Web of Science ®Google Scholar
• Bridging Study for Killed Oral Cholera Vaccine in Ethiopia. NCT01524640. 2012 [cited February 23, 2013]; Available from: http://clinicaltrials.gov/ct2/show/NCT01524640?term=oral+cholera+vaccine%2C+ethiopia&rank=1.
   Google Scholar
• Desai SN, et al. Evaluation of a Boosting Regimen With Oral Cholera Vaccine. NCT01579448. in Vaccines and Enteric Diseases. 2013. Bangkok.
   Google Scholar
• Coalition for Cholera Prevention and Control. Comprehensive Integrated Strategy for Cholera Prevention and Control. 2013.
   Google Scholar
• Walker RI, Steele D, Aguado T, Ad Hoc ETEC Technical Expert Committee. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 2007; 25:2545 - 66; http://dx.doi.org/10.1016/j.vaccine.2006.12.028; PMID: 17224212
   PubMed Web of Science ®Google Scholar
• Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 2011; 29:1347 - 54; http://dx.doi.org/10.1016/j.vaccine.2010.10.035; PMID: 21040694
   PubMed Web of Science ®Google Scholar
• Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606 - 14; http://dx.doi.org/10.1016/S0140-6736(10)60889-6; PMID: 20692030
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289 - 98; http://dx.doi.org/10.1056/NEJMoa0904797; PMID: 20107214
   PubMed Web of Science ®Google Scholar
• Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 2011; 5:e1289 - 1289; http://dx.doi.org/10.1371/journal.pntd.0001289; PMID: 22028938
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336:891 - 4; http://dx.doi.org/10.1016/0140-6736(90)92266-K; PMID: 1976928
   PubMed Web of Science ®Google Scholar
• Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926 - 39; http://dx.doi.org/10.1093/clinids/13.5.926; PMID: 1660184
   PubMedGoogle Scholar